Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia.

Study answer

What this study found

Vitamin B6 appeared to reduce tardive dyskinesia severity compared with placebo, but the evidence base was small and imprecise. The pooled global clinical efficacy result favored vitamin B6, with RR 19.97 (95% CI 2.87 to 139.19; n = 65 across 2 studies), and the pooled endpoint ESRS tardive dyskinesia score was lower by MD -4.07 (95% CI -6.36 to -1.79; n = 60 across 2 studies). Individual trials also showed lower endpoint ESRS scores with vitamin B6, including 2.3 (2.7) vs 8 (3.8) at week 4 and 4.7 (4.32) vs 7.4 (6.11) at week 12. Adverse events and discontinuation were uncommon but reported…

Study & population

This was a systematic review/meta-analysis of 3 randomized placebo-controlled trials in adults with schizophrenia or schizoaffective disorder who had neuroleptic-induced tardive dyskinesia.

Intervention

Vitamin B6, also referred to as pyridoxal 5 phosphate or pyridoxal phosphate, was tested as an add-on to ongoing antipsychotic treatment.

Key limitation

Overall certainty was low because only 3 small trials were available, follow-up was short, and trial design/reporting limitations were noted.

View full study detailsView sourceOpen PDF

Original abstract